Spyre Therapeutics, Inc. (SYRE)
- Previous Close
34.10 - Open
34.12 - Bid 35.05 x 100
- Ask 35.30 x 200
- Day's Range
33.85 - 35.34 - 52 Week Range
2.65 - 47.97 - Volume
334,472 - Avg. Volume
387,833 - Market Cap (intraday)
1.784B - Beta (5Y Monthly) 2.93
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.00
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
www.spyre.comRecent News: SYRE
Performance Overview: SYRE
Trailing total returns as of 6/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYRE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYRE
Valuation Measures
Market Cap
1.78B
Enterprise Value
1.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
770.13
Price/Book (mrq)
--
Enterprise Value/Revenue
2.37k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.93%
Return on Equity (ttm)
-391.81%
Revenue (ttm)
688k
Net Income Avi to Common (ttm)
-364.22M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
484.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.34M